GlassScriptPhysician profile
Anthony R Ignocheck
NPI 1023017894
$4,945.54
in general payments reported to CMS, 2019-2025
22 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $209 · 2021: $244 · 2022: $521 · 2023: $978 · 2024: $937 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $864.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $779.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $539.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Pediarix |
| Pfizer INC. | $486.25 | 2019-2025 | |
| Alkermes, INC. | $437.34 | 2019-2024 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $429.14 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $303.43 | 2022-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.74 | 2019-2025 | Spiriva Respimat, Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $226.52 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Braeburn INC. | $124.90 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $90.92 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.75 | 2021-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.19 | 2025 | Caplyta |
| Amgen INC. | $34.83 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $32.85 | 2023-2024 | Camzyos, Eliquis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $32.42 | 2023 | Symtuza |
| Qiagen, LLC | $28.76 | 2024 | |
| Abbvie INC. | $19.60 | 2025 | |
| Gilead Sciences, INC. | $19.58 | 2025 | |
| Medtronic, INC. | $19.00 | 2025 | Inceptiv |
| Dexcom, INC. | $16.28 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ignocheck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.